Answering Pivotal Questions in the Diagnosis and Treatment of Primary Biliary Cirrhosis and Non-Alcoholic Steatohepatitis - European Medical Journal
×

Browse

Answering Pivotal Questions in the Diagnosis and Treatment of Primary Biliary Cirrhosis and Non-Alcoholic Steatohepatitis

| Download as | PDF
Chairpeople:
Michael Trauner1
Speakers:
David E.J. Jones,2 Vlad Ratziu3
Disclosure:

Michael Trauner has consulted for AbbVie, Albireo Pharma, Falk Pharma, Gilead, Intercept Pharmaceuticals, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., and Phenex Pharmaceuticals; and has received speaker honoraria from Falk Pharma, Genfit, and Merck Sharp & Dohme Corp. David E.J. Jones has consulted for GSK, Pfizer, and Intercept Pharmaceuticals; has received research funding (to UK-PBC) from Intercept Pharmaceuticals, GSK, and Lumena; and has received speaker honoraria from Falk Pharma. Vlad Ratziu has consulted for Intercept Pharmaceuticals, Genfit, Tobira, and Galmed.

Acknowledgements:

Writing assistance was provided by Dr Ewen Legg of Halcyon Medical Writing.

Support:

Medical writing assistance was funded by Intercept Pharmaceuticals, Inc. The views and opinions expressed are those of the authors as stated during the symposium and are not necessarily those of Intercept Pharmaceuticals, Inc.

Citation
EMJ Hepatol. ;3[2]:52-59.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

Professor Trauner introduced the subject of liver disease and its burden within the European Union (EU) and across the globe. Professor Jones summarised the progress made in understanding the pathophysiology of primary biliary cirrhosis (PBC), current unmet needs in the ursodeoxycholic acid (UDCA) era, and novel therapeutic options for PBC treatment. Professor Ratziu discussed the emerging understanding of the complex multisystem pathophysiology of non-alcoholic steatohepatitis (NASH), summarised the available therapeutic targets, and detailed the trials of novel agents currently underway.

Receive our free quarterly newsletters and your choice of journal publication alerts, straight to your inbox.

Join our mailing list

Please view the full content in the pdf above.